Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Beijing InnoCare to Start Phase III Combination Trial of BTK Inhibitor

publication date: Feb 5, 2021

Beijing InnoCare was approved to start a China Phase III trial of its Bruton’s tyrosine kinase (BTK) inhibitor in combination with R-CHOP as a first-line treatment for mantle cell lymphoma (MCL). In late 2020, orelabrutinib was approved by China's NMPA to treat relapsed/refractory MCL along with r/r chronic lymphocytic leukemia (and small lymphocytic lymphoma. In the US, orelabrutinib has Orphan Drug Designation for MCL. InnoCare expects it will be effective in several B-cell malignant lymphomas. More details....

Stock Symbol: (HK: 09969)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.